A distinct CAR-T cell phenotype mediates therapeutic response at limited doses. | ClinicLens
Chimeric antigen receptor (CAR) T-cell therapies are typically administered at high doses to maximize durable clinical responses. However, manufacturing constraints can limit the production of sufficient cells to achieve the intended dose. Although some patients experience durabl
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.